Results of the ARIEL4 study support the use of the PARP inhibitor rucaparib as an alternative to chemotherapy for patients with relapsed, BRCA1- or BRCA2-mutated ovarian cancer.
Reuters Health Information
Rucaparib Bests Chemo in Relapsed Ovarian Cancer
